Online inquiry

IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7983MR)

This product GTTS-WQ7983MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GHR gene. The antibody can be applied in Growth hormone (GH) deficiency research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000163.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2690
UniProt ID P10912
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7983MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14219MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ2746MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ10672MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ3293MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ11209MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ8875MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ7853MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ3940MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW